vs
Apellis Pharmaceuticals, Inc.（APLS）与Accelerant Holdings（ARX）财务数据对比。点击上方公司名可切换其他公司
Accelerant Holdings的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$267.4M vs $199.9M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -511.9%，领先482.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Accelerant Holdings是一家全球特种保险与再保险科技平台，依托先进数据分析和风险评估工具，为保险公司、总代理及承保合作伙伴提供定制化风险解决方案，优化承保流程，业务覆盖北美及欧洲的商业和特种保险领域。
APLS vs ARX — 直观对比
营收规模更大
ARX
是对方的1.3倍
$199.9M
净利率更高
APLS
高出482.4%
-511.9%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $267.4M |
| 净利润 | $-59.0M | $-1.4B |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -507.7% |
| 净利率 | -29.5% | -511.9% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $-6.99 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSARX
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $267.4M | ||
| Q2 25 | $178.5M | $219.1M | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | — | ||
| Q3 24 | $196.8M | — | ||
| Q2 24 | $199.7M | — | ||
| Q1 24 | $172.3M | — |
净利润APLSARX
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-1.4B | ||
| Q2 25 | $-42.2M | $8.8M | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | — | ||
| Q2 24 | $-37.7M | — | ||
| Q1 24 | $-66.4M | — |
营业利润率APLSARX
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | -507.7% | ||
| Q2 25 | -18.6% | 10.2% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — | ||
| Q1 24 | -36.0% | — |
净利率APLSARX
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -511.9% | ||
| Q2 25 | -23.6% | 4.0% | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | — | ||
| Q2 24 | -18.9% | — | ||
| Q1 24 | -38.5% | — |
每股收益（稀释后）APLSARX
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $-6.99 | ||
| Q2 25 | $-0.33 | $0.04 | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $1.6B |
| 总债务越低越好 | — | $121.9M |
| 股东权益账面价值 | $370.1M | $676.1M |
| 总资产 | $1.1B | $7.9B |
| 负债/权益比越低杠杆越低 | — | 0.18× |
8季度趋势，按日历期对齐
现金及短期投资APLSARX
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $1.6B | ||
| Q2 25 | $370.0M | $1.4B | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSARX
| Q4 25 | — | — | ||
| Q3 25 | — | $121.9M | ||
| Q2 25 | — | $126.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSARX
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $676.1M | ||
| Q2 25 | $156.3M | $346.2M | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | — | ||
| Q3 24 | $237.1M | — | ||
| Q2 24 | $264.3M | — | ||
| Q1 24 | $266.7M | — |
总资产APLSARX
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $7.9B | ||
| Q2 25 | $821.4M | $7.5B | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | — | ||
| Q3 24 | $901.9M | — | ||
| Q2 24 | $904.5M | — | ||
| Q1 24 | $831.9M | — |
负债/权益比APLSARX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.37× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $73.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSARX
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $73.9M | ||
| Q2 25 | $4.4M | $309.3M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | — | ||
| Q3 24 | $34.1M | — | ||
| Q2 24 | $-8.3M | — | ||
| Q1 24 | $-133.0M | — |
自由现金流APLSARX
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSARX
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSARX
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSARX
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 35.15× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ARX
| Underwriting Segment | $117.6M | 44% |
| Exchange Services Segment | $85.0M | 32% |
| Other | $64.8M | 24% |
